Massive haemoptysis in ICU

Definition

[1]

There is no single universally agreed volume threshold for "massive" haemoptysis. The classical range quoted across textbooks is >100-600 mL/24 h; the most widely used operational definition is >200 mL/24 h, and many units add any bleeding that threatens the airway or causes haemodynamic instability as an equivalent trigger. The reason volume is an imperfect marker: the tracheobronchial tree of a supine, intubated patient can be flooded by a comparatively small volume, so asphyxiation risk rather than blood loss dictates urgency.[1] A practical ICU rule — any haemoptysis that contaminates the contralateral lung or impairs ventilation is massive, regardless of mL.[5]

Pathophysiology — why the bronchial circulation matters

The lung has a dual blood supply: [1]

• Pulmonary circulation — low pressure (~15/8 mmHg), carries entire cardiac output. Bleeding here is usually slower and tamponades easily.
• Bronchial circulation — systemic pressure (~120/80 mmHg), arises from the descending aorta, supplies airways and is the source of ~90% of massive haemoptysis.[1]

Inflammatory, infective and neoplastic processes drive bronchial arterial hypertrophy, neovascularisation and shunting from the high-pressure systemic bronchial arteries into the low-pressure pulmonary vasculature. Because these vessels are at systemic pressure, rupture produces brisk, voluminous haemorrhage — far more dangerous than a pulmonary-artery source of similar size. This single anatomical fact explains both the urgency (asphyxiation) and the rationale for bronchial artery embolisation as first-line definitive therapy.[7]

Causes

Key causes to commit to memory for the exam — bronchiectasis (overall #1), lung cancer, tuberculosis (active + old cavity with aspergilloma), pulmonary embolism (haemorrhagic infarct), pulmonary vasculitis (GPA/Goodpasture's — diffuse alveolar haemorrhage), and pulmonary AVM (hereditary haemorrhagic telangiectasia).[6]

Diffuse alveolar haemorrhage (DAH) — a distinct subset

Not all massive haemoptysis is focal. Diffuse alveolar haemorrhage from capillaritis produces bilateral alveolar infiltrates with (often surprisingly little) haemoptysis, anaemia out of proportion to visible blood, and progressive hypoxaemia. Causes are immunological (ANCA-associated vasculitis/GPA, anti-GBM/Goodpasture's, SLE, APLA) or non-immunological (idiopathic pulmonary haemosiderosis, coagulopathy, mitral stenosis, drug toxicity). Bronchoalveolar lavage shows progressively bloodier return from successive aliquots. Management is immunosuppression (high-dose corticosteroids ± cyclophosphabmide/rituximab) ± plasma exchange (anti-GBM), not BAE — because there is no single target vessel.[1]

Management

[1] [1]

Airway and lung isolation

Practical pearls[8][9] — use the largest single-lumen ETT that fits (≥8.0 mm) if a bronchoscope or blocker will pass; prefer a left-sided DLT because the right main bronchus is short and the right upper lobe orifice is easily occluded; exchange a tube only if you can visualise the glottis — a blood-flooded airway converts a tube exchange into an airway disaster.[2]

Bronchoscopic haemostasis

[1]

These are temporising measures that buy time for definitive BAE or surgery; few provide durable control in brisk bleeding.[4][2]

Bronchial artery embolisation (BAE) — first-line definitive

[1]

Surgery — lobectomy for refractory disease

Surgery is reserved for: BAE unavailable or failed, localised surgical cause (resectable cancer, AVM, mycetoma in a fit patient), or massive ongoing bleed with no IR access. Procedure is lobectomy (or segmentectomy for peripheral lesions) — pneumonectomy is avoided when possible due to high mortality. Emergency surgery carries 20-40% mortality (aspiration, haemodynamic collapse); the same operation done electively after BAE carries only 5-10% mortality. Aspergilloma with recurrent post-BAE re-bleed is the classic elective lobectomy indication.[3][6]

Differential diagnosis — true haemoptysis vs mimics

[1]

Always perform an ENT examination (anterior nasal vessels, posterior epistaxis, oropharyngeal bleeding) before attributing blood to the lower airway — pseudohaemoptysis is a common pitfall.[6]

Investigation

Pharmacology adjuncts

• Tranexamic acid (TXA) — modest evidence; IV 1 g then infusion, or nebulised 250-500 mg. An integrative review supports a trial, especially while awaiting definitive therapy.[10]
• Vasopressin / terlipressin — seldom used; systemic vasoconstriction risks; superseded by selective BAE.
• Antitussives — suppress cough (codeine) to reduce mechanical disruption of clot — but avoid over-sedation that impairs airway protection.
• Coagulation correction — FFP (INR > 1.5), platelets (< 50 or antiplatelet), cryoprecipitate (fibrinogen < 1.5 g/L), vitamin K (warfarin), idarucizumab (dabigatran), andexanet alfa (apixaban/rivaroxaban), PCC.

Exam practice

[1] [1]

Clinical pearls

Red flags

Prognosis

[1] [1] [1] [1]

Comparison of definitive therapies

Anatomy for the exam

• Bronchial arteries — usually 2 left, 1 right; arise from descending thoracic aorta at T5-T6; may share origin with intercostal, subclavian, internal mammary, or coronary arteries.
• Non-bronchial systemic collaterals — intercostal, subclavian, internal mammary, inferior phrenic — can supply bleeding in chronic disease and must be sought if BAE fails (recurrent re-bleed).
• Artery of Adamkiewicz — major anterior spinal artery feeder; usually arises T9-L1 from an intercostal/lumbar, but aberrant origins exist — the spinal-ischaemia risk of BAE.
• Right upper lobe bronchus (RUL) — takeoff ~1 cm from carina — why right-sided DLTs are harder to position than left.
• Left main bronchus — longer, narrower, more vertical than right in some individuals (relevant to aspiration, not the often-quoted "right is more vertical" which describes the adult tracheobronchial tree — right main bronchus is wider, shorter and more vertical).[7][8]

Pitfalls and exam traps

• Treating the volume, not the airway. A "small" bleed flooding the contralateral lung is immediately fatal; a 500 mL slow ooze that the patient coughs up may not be. Triage on airway compromise.
• Positioning the GOOD side down. Catastrophic — floods the only functioning lung. Bleeding side DOWN.
• Tube exchange in a blood-flooded airway. If the single-lumen tube is working, keep it and use a blocker; lost view = lost airway.
• Attributing DAH to a focal cause and sending for BAE. Capillaritis needs immunosuppression, not embolisation.
• Forgetting non-bronchial systemic collaterals after a failed BAE — they are the usual reason for early recurrence.
• Anticoagulating a patient with recent massive haemoptysis for a "PE" — confirm the diagnosis; haemorrhagic PE infarct bleeds may be controlled by stopping, not escalating, anticoagulation, while true PE still needs treatment. Multidisciplinary decision.[1][6]

Key takeaways

1. Airway first, position bleeding side down, isolate the good lung.
2. 90% of bleeding is bronchial (systemic, high-pressure) — hence BAE first-line.
3. Bronchoscopy localises and temporises; CT defines cause and vascular anatomy.
4. BAE = 70-90% immediate success; surgery = last resort, lobectomy for refractory/localised disease.
5. DAH/vasculitis is a different disease — immunosuppression, not embolisation.
6. Anticipate re-bleed (10-30%) and post-bleed aspiration pneumonia — antibiotics, follow-up, elective definitive therapy. [1]

References

1. [1]Ittrich H, Bockhorn M, Klose H, Simon M, et al. The Diagnosis and Treatment of Hemoptysis Dtsch Arztebl Int, 2017.PMID 28625277
2. [2]Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management Respiration, 2010.PMID 20090288
3. [3]Kettenbach J, Ittrich H, Gaubert JY, et al. CIRSE Standards of Practice on Bronchial Artery Embolisation Cardiovasc Intervent Radiol, 2022.PMID 35396612
4. [4]Valipour A, Kreuzer A, Koller H, Koessler W, Burghuber OC. Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis Chest, 2005.PMID 15947328
5. [5]Jean-Baptiste E. Clinical assessment and management of massive hemoptysis Crit Care Med, 2000.PMID 10834728
6. [6]Larici AR, Franchi P, Occhipinti M, et al. Diagnosis and management of hemoptysis Diagn Interv Radiol, 2014.PMID 24808437
7. [7]Ittrich H, Klose H, Adam G. Radiologic management of haemoptysis: diagnostic and interventional bronchial arterial embolisation Rofo, 2015.PMID 25372159
8. [8]Campos JH, Musselman ED, Hanada S, et al. Lung Isolation Techniques in Patients With Early-Stage or Long-Term Tracheostomy: A Case Series Report of 70 Cases and Recommendations J Cardiothorac Vasc Anesth, 2019.PMID 30190202
9. [9]Collins SR, Titus BJ, Campos JH, et al. Lung Isolation in the Patient With a Difficult Airway Anesth Analg, 2018.PMID 29189274
10. [10]Ye M, Chen M, Wang C, et al. Nebulized Tranexamic Acid in the Management of Hemoptysis: An Integrative Review Lung, 2025.PMID 39841268